Centessa Pharmaceuticals company information, Employees & Contact Information

Clinical-Stage Pharma Centessa to Present Latest Developments at Morgan Stanley Healthcare Conference Stock Titan

Centessa Pharmaceuticals Advances OX2R Agonist Pipeline with Key Clinical Data Readouts Scheduled for 2025 Quiver Quantitative

BRIEF—Centessa’s ORX142 milestone triggers Nxera payment The Pharma Letter

Centessa Pharmaceuticals: Smooth Move To New Programs, But Questions Remain (NASDAQ:CNTA) Seeking Alpha

Centessa Pipeline Advances: Key Sleep Disorder Drug Shows Promise, Multiple Data Readouts Coming in 2025 Stock Titan

Centessa Pharmaceuticals to Present Phase 1 Clinical Data of OX2R Agonist ORX750 at AAN 2025 Annual Meeting Quiver Quantitative

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update GlobeNewswire

Centessa drops phase 2 hemophilia B drug in wake of Pfizer’s Hympavzi approval Fierce Biotech

Investors are waking up to Centessa’s sleepiness drug BioPharma Dive

Centessa Pharmaceuticals to Present at Jefferies and Goldman Sachs Healthcare Conferences in June Stock Titan

Centessa Pharmaceuticals: Orexin Franchise Worth Monitoring Seeking Alpha

LifeSci Capital Reaffirms Buy Rating on Centessa Pharmaceuticals (CNTA) with a $39 PT, Anticipates Key Orexin Pipeline Data Yahoo Finance

Centessa Pharmaceuticals Launches with $250 Million Series A Financing and Unveils a New Kind of Pharmaceutical R&D Model Business Wire

Centessa to Advance Orexin Agonist ORX142 to Clinical Trials Following IND Acceptance NeurologyLive

Centessa Pharmaceuticals Appoints Stephen Kanes MD PhD as Chief Medical Officer Quiver Quantitative

Centessa's Novel Sleep Drug Pipeline Targets $25B Market with Three Clinical Readouts This Year Stock Titan

Is Centessa Pharmaceuticals plc (CNTA) the Best Small Cap Stock to Buy with the Biggest Upside Potential? Yahoo Finance

Centessa's New Sleep Disorder Drug Gets FDA Green Light, Clinical Data Coming in 2025 Stock Titan

Centessa Pharmaceuticals (CNTA) Upgraded to Buy: What Does It Mean for the Stock? Yahoo Finance

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) Stock Titan

Centessa Pharmaceuticals Plc (CNTA): A Small-Cap Leader in Clinical-Stage Biotech Yahoo Finance

Building Post-IPO Excellence at Centessa Pharmaceuticals FTI Consulting

Analysts Rate Centessa Pharmaceuticals Plc (CNTA) as Strong Buy Amid Promising Developments Yahoo Finance

Centessa Pharma general counsel sells $131k in shares Investing.com

Why Is Centessa Pharmaceuticals (CNTA) Among the Best Medical Stocks to Buy Under $20? Yahoo Finance

Centessa Pharmaceuticals plc (CNTA) reports earnings qz.com

Centessa Pharmaceuticals’ Accardi sells $210,000 in shares Investing.com

Biotech Soars, And Then Dives, On $5 Billion Opportunity Investor's Business Daily

Centessa Pharma (CNTA) CBO Weinhoff sells $138k in shares Investing.com

Stocks To Watch: Centessa Pharma ADR Sees RS Rating Jump To 92 Investor's Business Daily

Centessa Appoints Neuropsychiatrist as Chief Medical Officer Sleep Review

Centessa dumps top program after evidence of tolerability issues stunt market potential Fierce Biotech

Centessa Pharmaceuticals: forging a new path for pharma R&D Pharmaceutical Technology

Centessa Pharmaceuticals: Progressing SerpinPC Through Registrational Trials In Hemophilia B Seeking Alpha

Nxera Pharma’s Partner Centessa Initiates Phase 2 Trial with ORX750, a Novel Orexin Receptor 2 (OX2R) Agonist GlobeNewswire

Centessa Pharma hoping for $250M IPO to top January series A and fund initial drug development Fierce Biotech

Centessa raises $330M in third largest biotech IPO this year BioPharma Dive

Centessa reports positive phase 1 clinical data for ORX750 PharmaTimes

10 biotechs become 1: Centessa launches with $250M to prove unorthodox R&D model BioPharma Dive

Anaptys picks up rival to Biogen autoimmune asset from Centessa Fierce Biotech

Centessa eyes registration in hemophilia as SerpinPC shows reduction of bleeding in phase 2 study Fierce Biotech

Elevated liver enzymes force Centessa to drop a 2nd asset in 2 months Fierce Biotech

Activation of tolvaptan-responsive T-cell clones with the structurally-related mozavaptan ScienceDirect.com

Moncef Slaoui is joining Centessa, a new drug company backed with $250 million. Here's how the former head of Operation Warp Speed plans to grow it into the next pharma giant. businessinsider.com

Slaoui's Centessa adds ex-FDA commish Califf, biotech bigwigs to its board Fierce Biotech

Newly-Launched Centessa Pharmaceuticals Already Planning $100 Million IPO BioSpace

Safety Signal Leads Centessa to Discontinue Development of Lead Asset BioSpace

Check out Centessa Pharmaceuticals PLC's stock price (CNTA) in real time CNBC

Travers Smith advises Medicxi on Centessa Pharmaceuticals Travers Smith

Centessa Pharmaceuticals (NASDAQ:CNTA) Raised to “Hold” at Wall Street Zen Defense World